Management of CV Risk & T2DM: Implications of novel outcome trials
Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona
Video navigation menu
Diabetes is a major CV risk factor 00:27
The focus in the past was on reducing traditional CV risk factors in diabetes patients. 02:23
SGLT2 inhibitors and GLP1 agonists, new types of diabetes drugs, show a CV advantage 05:16
Interesting new studies ahead on SGLT2 inhibitors and GLP1 agonists alone or in combination, also in patients who do not have diabetes 11:04
Educational information
The educational objectives of this symposium were to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
Faculty
Prof. John E Deanfield, MD is Professor of Cardiology, Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom
CME Accreditation
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Disclosures
This symposum was supported by an unrestricted educational grants provided by Boehringer-Ingelheim/Lilly